Supplementary Fig. 2 Reversal of acquired resistance and BRAF expression in HT6244-R cells is apparent following 5 weeks selumetinib withdrawal and complete by 10 weeks. a, b Non-clonal HT6244-R cells (R) were single-cell sorted, expanded and 12 clonal cell lines (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) were treated with 1 μM selumetinib (Sel) (a) or selumetinib-free medium (b) for 24 hours. In parallel parental HT29 cells (P) were treated with selumetinib-free medium for 24 hours. Lysates were western blotted with the indicated antibodies. c, d Following culture in the presence (+) or absence (HT29, (−)) of 1 μM selumetinib for the indicated times, cells were treated with increasing concentrations (10 nM to 10 μM) of selumetinib (Sel) for 24 hours, and DNA synthesis assayed by [ 3 H]thymidine incorporation (c), or incubated in selumetinib-free medium for 24 hours and lysates western blotted with the indicated antibodies (d). HT6244-R C1 and C2 are single cell clone derivative cell lines of HT6244-R. Results (c) are mean ± SD of cell culture triplicates and normalized to control for each cell line. e HT29 and HT6244-R cells were treated with 1 μM selumetinib (HT6244-R + Sel) or DMSO only (HT29, HT6244-R − Sel) for 3 or 9 days and images captured using brightfield phase contrast microscopy. Scale bars indicate 100 μm. PPP3CC  EGFR  MAPKAPK2  MAP3K1  PDGFB  MAP2K4  MAP2K1  MAP2K3  RRAS2  RELB  TAOK1  FLNB  RAC2  BRAF  MAP3K5   MAP3K11  FGF9  TAOK2  PPP3CB   PPP3R1   PPP3CA  HSPA8  TGFB3   GRB2   NFKB2  PLA2G2F  MAP2K2  TNFRSF1A   RPS6KA4  MAP4K3  MAP3K7   MAP3K14   CDC25B  KRAS  GNG12   RPS6KA2  MAPK9  IL1B   NRAS  STK4   DUSP5  DUSP6  FLNA  GADD45A  FOS  RRAS  TGFBR2  MAPKAPK3   JUN  DDIT3  RAPGEF2  FASLG  GADD45B  DUSP1  DUSP3  MKNK2  CACNA2D4 C6244-R + Sel C6244-R − Sel IGFBP1  ISG15  RAB5B  CDKN2B  MMP1  HTATIP2  ALDH1A3  CDKN2D  THBS1  TSPYL5  CXCL14   CCND1  RRAS  MAP1LC3B  SMPD1  SERPINE1  RHOB  GSN  S100A11   CLTB  IRF7  MAP2K3  OPTN  TES  CDKN1A  HPS5  IGSF3 Supplementary Fig. 4 Positive cell cycle regulators are typically downregulated following MEKi withdrawal from C6244-R cells while negative regulators are enriched. a-c C6244-R cells were treated with 1 μM selumetinib (+ Sel) or DMSO only (− Sel) for 4, 16 or 48 hours. RNA was extracted and subjected to microarray analysis, from which enrichment of cell cycle genes (gene set curated by Kyoto Encyclopedia of Genes and Genomes (KEGG)) was evaluated (a) and cell cycle genes upregulated (b) or downregulated (c) plotted. NES, normalized enrichment score; FDR, false discovery rate. d, e C6244-R cells were left untransfected (UT), transfected with non-targeting (NT) siRNA or transfected with p21
CIP1
-specific siRNA (p21). COLO205 and HCT116 (C) cells were included as untransfected (UT) controls as indicated. 24 hours after transfection cells treated with 1 μM selumetinib (Sel; +) or DMSO only (−) for 4 hours and lysates harvested for western blotting (d) or for 48 hours and cell cycle profile assessed by flow cytometry (e). P < 0.001 (***) or P > 0.05 (ns) determined by oneway ANOVA with Tukey's multiple comparisons test of the G1 fractions. f, g C6244-R (f) or HT6244-R (g) cells were treated with selumetinibfree media (− Sel) for the indicated time periods (0-72 hours). COLO205 (f) or HT29 (g) cells were included as time 0 controls, and HeLa cells included as positive control for p16
INK4A expression (C). Lysates were western blotted with the indicated antibodies.
Supplementary Fig. 5 CDKN1C/p57
KIP2 knockout inhibits the reversal of selumetinib resistance in C6244-R cells. a, b Wild type (p57 WT1) and knockout (p57 KO1, p57 KO2) C6244-R cells generated by CRISPR/Cas9 gene editing with guide RNA (gRNA#2) targeting CDKN1C (encoding p57 KIP2 ) were cultured in the presence (+) or absence (COLO205, (−)) of 1 μM selumetinib for the indicated times. Cells were then treated with increasing concentrations (10 nM to 10 μM) of selumetinib (Sel) for 24 hours, and DNA synthesis assayed by [
3 H]thymidine incorporation (a), or incubated in selumetinib-free medium for 24 hours and lysates western blotted with the indicated antibodies (b). Results (a) are mean ± SD of cell culture triplicates and normalized to control for each cell line. 
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Supplementary Fig. 6 CDKN1C/p57 KIP2 is required for cell cycle arrest and reversal of resistance upon MEKi withdrawal from C6244-R cells. a, b Wild type (p57 WT2) and knockout (p57 KO3, p57 KO4) C6244-R cells generated by CRISPR/Cas9 gene editing with guide RNA (gRNA#1) targeting CDKN1C (encoding p57 KIP2 ) were treated with (+) selumetinib (Sel) or DMSO only (−) for 72 hours. Untransfected COLO205 and C6244-R cells were included as controls. Cells were western blotted with the indicated antibodies (a) or cell cycle profile determined by flow cytometry (b). Results (b) are mean ± SD of four independent experiments. P < 0.001 (***) or P > 0.05 (ns) determined by one-way ANOVA with Tukey's multiple comparisons test of the G1 fractions. c, d Following culture in the presence (+) or absence (−) of 1 μM selumetinib for the indicated times, cells were treated with increasing concentrations (10 nM to 10 μM) of selumetinib (Sel) for 24 hours, and DNA synthesis assayed by [
3 H]thymidine incorporation (c), or incubated in selumetinib-free medium for 24 hours and lysates western blotted with the indicated antibodies (d). Results (c) are mean ± SD of cell culture triplicates and normalized to control for each cell line. Supplementary Fig. 13 EMT induced by MEKi withdrawal is ERK1/2-dependent and associated with enhanced cell motility and chemoresistance. a HCT116 and H6244-R cells were treated with 2 μM selumetinib (+ Sel) or DMSO only (HCT116, − Sel) for the indicated times. b LoVo and L6244-R cells were treated with 4 μM selumetinib (+ Sel) or DMSO only (LoVo, − Sel) for the indicated times. c L6244-R cells were treated with the indicated concentrations of SCH772984 in the absence of selumetinib (− Sel) for 72 hours. LoVo, and L6244-R cells treated with 4 μM selumetinib (+), were included as controls. a-c Lysates were western blotted with the indicated antibodies, and A549 cells were used for positive control (C), except for SNAI2 (SW620 cells). Results are representative of at least two experiments giving equivalent results. d, e H6244-R cells were treated with 2 μM selumetinib (H6244-R + Sel) or DMSO only (HCT116, H6244-R − Sel) for 9 days. Confluent cell monolayers were scratched and wound healing monitored at the indicated times. Representative results (d) are shown with mean ± SD of three independent experiments (e). P < 0.05 (*) or P > 0.05 (ns) determined by unpaired two-tailed t-test. Scale bar indicates 1 mm. f, g LoVo and L6244-R cells were treated with 4 μM selumetinib (L6244-R + Sel) or DMSO only (LoVo, L6244-R − Sel) for 9 days. Cell movements were then tracked every 10 minutes for the following 16 hours. Spider diagrams of individual cell paths (f) are shown with mean accumulated and Euclidean distance ± SD (n > 300 cells for each cell line) (g). P < 0.001 (***) determined by one-way ANOVA with Tukey's multiple comparisons test. h-j LoVo and L6244-R cells were treated with 4 μM selumetinib (L6244-R + Sel) or DMSO only (LoVo, L6244-R − Sel (9 d)) for 9 days. The following day cells were treated with the indicated concentrations of oxaliplatin for 24 (h) or 72 (i) hours, or 5-fluorouracil for 72 hours (j), maintaining prior presence or absence of selumetinib. As a control, L6244-R cells maintained in selumetinib throughout were switched to selumetinib free-medium for the final 24 hours of treatment (L6244-R -Sel (24 h 
